A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
Terminated · Phase 1, Phase 2 · NCT06508489
Conditions: Acute Myeloid Leukemia
At a glance
- Research payments reported, 2025
- $855,677
- U.S. investigators named
- 6
- Sites paid
- 8
- Planned or actual enrollment
- 7
About the trial
- Sponsor
- Sanofi
- Tested
- SAR443579 (biological), venetoclax (drug), azacitidine (drug)
- Dates
- Started 2024-08-13; completion 2025-08-08
- Results posted
- Yes
This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or adult participants with CD123 expressing hematological malignancies. This protocol was structured as a master protocol (containing common protocol elements). Individual sub-studies would explore SAR443579 with combination partners, which might include approved or investigational agents. Experimental sub-studies would be tested through 3 parts: Part 1: dose finding (such as dose escalation/ safety run-in). Part 2: dose optimization (when applicable). Part 3: dose expan…
From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $855,677 in research payments for this study in 2025 (29 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anthony Stein, MD Hematology · Duarte, CA
- Pinkal Desai, M.D. Hematology & Oncology · New York, NY
- Ioannis Mantzaris, M.D Legal Medicine (non-physician) · Bronx, NY
- Uma M. Borate, MD Hematology · Columbus, OH
- Jennifer N. Saultz, DO Internal Medicine · Portland, OR
- Abhishek Maiti, MD Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- City of Hope National Medical Ctr $362,521
- Ut MD Anderson Cancer Center $272,734
- Biomedical Research Alliance of New York LLC $73,893
- The Ohio State University the Ohio State University $45,687
- Ohsu Hospital and Clinics, OR $42,276
- The Ohio State University $30,191
- Weill Medical College of Cornell University Attn Joint Clinical Trials Office $28,375
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.